Board Must Reconsider Amendments To 2 Patent Claims Proposed By Pfizer
WASHINGTON, D.C. — In a review of five inter partes reviews (IPRs) by the Patent Trial and Appeal Board of patented pneumococcal vaccine technology, the Federal Circuit U.S. Court of Appeals...To view the full article, register now.
Already a subscriber? Click here to view full article